{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:45:05Z","timestamp":1765827905795,"version":"build-2065373602"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cardiogenic shock is a multifactorial and diverse entity in which inotropes are the cornerstone therapy. Although published clinical trials have focused on pharmacologic treatment of cardiogenic shock, there is lack of an established and widely accepted decision-making algorithm on the use of inotropic agents in cardiogenic shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The current review incorporates cardiogenic shock pathophysiology, inotropes and vasopressors pharmacodynamics. It emphasizes on each agent's indications, potential adverse effects, highlights special considerations and fsummarizes the recent guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Finally, proposes an algorithm of inotropes and vasopressors use and their potential combinations based on the clinical stage of cardiogenic shock. This algorithm can be used as a guide during the initial management of cardiogenic shock while underlying cause investigation is underway.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000744","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T18:15:30Z","timestamp":1591121730000},"page":"403-410","source":"Crossref","is-referenced-by-count":7,"title":["Inotropic agents in cardiogenic shock"],"prefix":"10.1097","volume":"26","author":[{"given":"Eftihia","family":"Polyzogopoulou","sequence":"first","affiliation":[{"name":"Emergency Medicine Department, Attikon University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Arfaras-Melainis","sequence":"additional","affiliation":[{"name":"Second Cardiology Department, Attikon Hospital, Medical School"},{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Bistola","sequence":"additional","affiliation":[{"name":"Second Cardiology Department, Attikon Hospital, Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Parissis","sequence":"additional","affiliation":[{"name":"Second Cardiology Department, Head of Emergency Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"R1-20231211","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"R2-20231211","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MCC.0000000000000632","article-title":"Inotropes and vasopressors use in cardiogenic shock: when, which and how much?","volume":"25","author":"Levy","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"R3-20231211","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-20231211","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20231211","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R6-20231211","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15420\/cfr.2019.11.2","article-title":"Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice","volume":"5","author":"Bistola","year":"2019","journal-title":"Card Fail Rev"},{"key":"R7-20231211","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/eurheartj\/ehv051","article-title":"Management of cardiogenic shock","volume":"36","author":"Thiele","year":"2015","journal-title":"Eur Heart J"},{"key":"R8-20231211","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00134-018-5214-9","article-title":"Management of cardiogenic shock complicating myocardial infarction","volume":"44","author":"Mebazaa","year":"2018","journal-title":"Intensive Care Med"},{"key":"R9-20231211","article-title":"Experts\u2019 recommendations for the management of adult patients with cardiogenic shock","volume":"5","author":"Levy","year":"2015","journal-title":"Ann Intensive Care"},{"key":"R10-20231211","first-page":"343","article-title":"Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline","volume":"109","author":"Werdan","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"R11-20231211","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/aas.12780","article-title":"Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure","volume":"60","author":"Moller","year":"2016","journal-title":"Acta Anaesthesiol Scand"},{"key":"R12-20231211","first-page":"CD009669","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"1","author":"Schumann","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20231211","first-page":"CD003709","article-title":"Vasopressors for hypotensive shock","volume":"2","author":"Gamper","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20231211","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/01.CIR.91.3.873","article-title":"Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators","volume":"91","author":"Hochman","year":"1995","journal-title":"Circulation"},{"key":"R15-20231211","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.amjcard.2015.01.010","article-title":"Long-term prognosis and risk heterogeneity of heart failure complicating acute myocardial infarction","volume":"115","author":"de Carvalho","year":"2015","journal-title":"Am J Cardiol"},{"key":"R16-20231211","doi-asserted-by":"crossref","first-page":"e103978","DOI":"10.1371\/journal.pone.0103978","article-title":"Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock","volume":"9","author":"den Uil","year":"2014","journal-title":"PLoS One"},{"key":"R17-20231211","article-title":"Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock","author":"Lewis","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R18-20231211","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40256-015-0134-3","article-title":"Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"R19-20231211","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1017\/S1047951105001411","article-title":"A Dobutamine paradox: eosinophilic myocarditis in the explanted heart of a 9-year-old girl undergoing cardiac transplantation","volume":"15","author":"Fenton","year":"2005","journal-title":"Cardiol Young"},{"key":"R20-20231211","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2003.12.069","article-title":"Dobutamine-induced eosinophilia","volume":"93","author":"El-Sayed","year":"2004","journal-title":"Am J Cardiol"},{"key":"R21-20231211","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0735-1097(02)02134-4","article-title":"Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol","volume":"40","author":"Metra","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R22-20231211","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/HCO.0000000000000057","article-title":"Pharmacologic therapies for acute cardiogenic shock","volume":"29","author":"Nativi-Nicolau","year":"2014","journal-title":"Curr Opin Cardiol"},{"key":"R23-20231211","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0167-5273(01)00520-4","article-title":"Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol","volume":"81","author":"Lowes","year":"2001","journal-title":"Int J Cardiol"},{"key":"R24-20231211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R25-20231211","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"R26-20231211","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R27-20231211","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"R28-20231211","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1097\/CCM.0000000000001269","article-title":"Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages","volume":"43","author":"Wang","year":"2015","journal-title":"Crit Care Med"},{"key":"R29-20231211","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s13054-014-0652-4","article-title":"Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model","volume":"18","author":"Tsao","year":"2014","journal-title":"Crit Care"},{"key":"R30-20231211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FJC.0000000000000636","article-title":"Use of levosimendan in intensive care unit settings: an opinion paper","volume":"73","author":"Herpain","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"R31-20231211","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1517\/13543784.17.8.1143","article-title":"Novel biologic mechanisms of levosimendan and its effect on the failing heart","volume":"17","author":"Parissis","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R32-20231211","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"R33-20231211","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur Heart J"},{"key":"R34-20231211","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"R35-20231211","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"R36-20231211","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"R37-20231211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejheart.2005.12.003","article-title":"Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE","volume":"8","author":"Cleland","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"R38-20231211","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis","volume":"42","author":"Fang","year":"2018","journal-title":"Med Intensiva"},{"key":"R39-20231211","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13054-016-1387-1","article-title":"Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality","volume":"20","author":"Tarvasm\u00e4ki","year":"2016","journal-title":"Crit Care"},{"key":"R40-20231211","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"R41-20231211","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","article-title":"Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial","volume":"172","author":"Triposkiadis","year":"2014","journal-title":"Int J Cardiol"},{"key":"R42-20231211","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/CCM.0b013e3181ffe0eb","article-title":"Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study","volume":"39","author":"Levy","year":"2011","journal-title":"Crit Care Med"},{"key":"R43-20231211","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R44-20231211","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00134-018-5222-9","article-title":"Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients","volume":"44","author":"L\u00e9opold","year":"2018","journal-title":"Intensive Care Med"},{"key":"R45-20231211","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.amjcard.2005.07.076","article-title":"Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction","volume":"96","author":"Jolly","year":"2005","journal-title":"Am J Cardiol"},{"key":"R46-20231211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00063-017-0378-6","article-title":"Vasopressors for acute myocardial infarction complicated by cardiogenic shock","volume":"114","author":"Prondzinsky","year":"2019","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"(4 Pt 2)","key":"R47-20231211","first-page":"H1228","article-title":"Effects of vasopressin on pulmonary and systemic vascular mechanics","volume":"257","author":"Wallace","year":"1989","journal-title":"Am J Physiol"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T08:05:40Z","timestamp":1702281940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000000744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000744","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"type":"print","value":"1070-5295"},{"type":"electronic","value":"1531-7072"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}